Review Article| Volume 36, ISSUE 4, P663-671, December 2016

Common Interferences in Drug Testing

  • Michael P. Smith
    Corresponding author. Toxicology and Therapeutic Drug Monitoring Laboratory, Beaumont Laboratories, Beaumont Hospital-Royal Oak, 3601 West 13 Mile Road, Royal Oak, MI 48073.
    Oakland University William Beaumont School of Medicine, Rochester, MI, USA

    Toxicology and Therapeutic Drug Monitoring Laboratory, Beaumont Laboratories, Beaumont Hospital-Royal Oak, 3601 West 13 Mile Road, Royal Oak, MI 48073, USA
    Search for articles by this author
  • Martin H. Bluth
    Department of Pathology, Wayne State University School of Medicine, 540 East Canfield, Detroit, MI 48201, USA

    Consolidated Laboratory Management Systems, 24555 Southfield Road, Southfield, Michigan 48075, USA
    Search for articles by this author


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.

      Content published before 2002 is available via pay-per-view purchase only.


      Subscribe to Clinics in Laboratory Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Johnson-Davis K.L.
        • Sadler A.J.
        • Gnzen J.R.
        A retrospective analysis of urine drugs of abuse immunoassay true positive rates at a National Reference Laboratory.
        J Anal Toxicol. 2016; 40: 97-107
        • Manchikanti L.
        • Malla Y.
        • Wargo B.W.
        • et al.
        Comparative evaluation of the accuracy of immunoassay with liquid chromatography tandem mass spectrometry (LC/MS/MS) of urine drug testing (UDT) opioids and illicit drugs in chronic pain patients.
        Pain Physician. 2011; 14: 174-187
        • Saitman A.
        • Park H.
        • Fitzgerald R.L.
        False-positive interferences of common urine drug screen immunoassays: a review.
        J Anal Toxicol. 2014; 38: 387-396
        • Brahm N.C.
        • Yeager L.L.
        • Fox M.D.
        • et al.
        Commonly prescribed medications and potential false-positive urine drug screens.
        Am J Health Syst Pharm. 2010; 67: 1344-1350
        • Moeller K.E.
        • Lee K.C.
        • Kissack J.C.
        Urine drug screening: practical guide for clinicians.
        Mayo Clin Proc. 2008; 83: 66-76
      1. Federal Register/Vol. 80. No. 94/pg. 28101–28151.

        • Kirsh K.L.
        • Christo P.J.
        • Heit H.
        • et al.
        Specimen validity testing in urine drug monitoring of medications and illicit drugs: clinical implications.
        J Opioid Manag. 2015; 11: 53-59
      2. SAMHSA. Medical review officer manual for federal agency workplace drug testing programs, 2010. Available at: Accessed August 25, 2016.

        • Dobson E.L.
        • Warner G.F.
        • Finney C.R.
        • et al.
        The measurement of liver circulation by means of the colloid disappearance rate: I. Liver blood flow in normal young men.
        Circulation. 1953; 7: 690-695
        • Winek C.L.
        • Murphy K.L.
        • Winek T.A.
        The unreliability of using a urine ethanol concentration to predict a blood ethanol concentration.
        Forensic Sci Int. 1984; 25: 277-281
      3. European Medicines Agency. Suboxone- EPAR-Scientific Discussion; 2006. Available at: Accessed August 25, 2016.

        • Cone E.J.
        • Huestis M.
        Interpretation of oral fluid tests for drugs of abuse.
        Ann N Y Acad Sci. 2007; 1098: 51-103
        • Verstraete A.G.
        Detection times of drugs of abuse in blood, urine, and oral fluid.
        Ther Drug Monit. 2004; 26: 200-205
        • Reisfield G.M.
        • Bertholf R.
        • Barkin R.L.
        • et al.
        Urine drug test interpretation: what do physicians know?.
        J Opioid Manag. 2007; 3: 80-86
        • ElSohly M.A.
        Urinalysis and casual handling of marijuana and cocaine.
        J Anal Toxicol. 1991; 15: 46
        • Baselt R.C.
        • Chang J.Y.
        • Yoshikawa D.M.
        On the dermal absorption of cocaine.
        J Anal Toxicol. 1990; 14: 383-384
        • Niedbala R.S.
        • Kardos K.W.
        • Fritch D.F.
        • et al.
        Passive cannabis smoke exposure and oral fluid testing. II. Two studies of extreme cannabis smoke exposure in a motor vehicle.
        J Anal Toxicol. 2005; 29: 607-615
        • Mulé S.J.
        • Lomax P.
        • Gross S.J.
        Active and realistic passive marijuana exposure tested by three immunoassays and GC/MS in urine.
        J Anal Toxicol. 1988; 12: 113-116
        • Niedbala S.
        • Kardos K.
        • Salamone S.
        • et al.
        Passive cannabis smoke exposure and oral fluid testing.
        J Anal Toxicol. 2004; 28: 546-552
        • Herrmann E.S.
        • Cone E.J.
        • Mitchell J.M.
        • et al.
        Non-smoker exposure to secondhand cannabis smoke II: effect of room ventilation on the physiological, subjective, and behavioral/cognitive effects.
        Drug Alcohol Depend. 2015; 151: 194-202
        • Cone E.J.
        • Bigelow G.E.
        • Herrmann E.S.
        • et al.
        Nonsmoker exposure to secondhand cannabis smoke. III. Oral fluid and blood drug concentrations and corresponding subjective effects.
        J Anal Toxicol. 2015; 39: 497-509
        • Bogusz M.J.
        • Hassan H.
        • Al-Enazi E.
        • et al.
        Application of LC-ESI-MS-MS for detection of synthetic adulterants in herbal remedies.
        J Pharm Biomed Anal. 2006; 41: 554-564
        • Liu S.Y.
        • Woo S.O.
        • Koh H.L.
        HPLC and GC-MS screening of Chinese proprietary medicine for undeclared therapeutic substances.
        J Pharm Biomed Anal. 2001; 24: 983-992
        • Piekoszewski W.
        • Florek E.
        The role of laboratory examinations in medical toxicology.
        Przegl Lek. 2005; 62: 954-959
        • Chen P.
        • Braithwaite R.A.
        • George C.
        • et al.
        The poppy seed defense: a novel solution.
        Drug Test Anal. 2014; 6: 194-201
        • Ward M.B.
        • Hackenmueller S.A.
        • Strathmann F.G.
        • Education Committee of the Academy of Clinical Laboratory Physicians and Scientists
        Pathology consultation on urine compliance testing and drug abuse screening.
        Am J Clin Pathol. 2014; 142: 586-593